Aadi Logo.jpg
Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting
May 26, 2022 17:10 ET | Aadi Bioscience
LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined...
Aadi Logo.jpg
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 07:00 ET | Aadi Bioscience
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined...
Aadi Logo.jpg
UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 08:32 ET | Aadi Bioscience
FYARRO net product sales of $2.3 million in partial first quarterDosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or...
Aadi Logo.jpg
Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022 07:00 ET | Aadi Bioscience
FYARRO net product sales of $2.3 million in partial first quarterDosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or...
Aadi Logo.jpg
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
May 09, 2022 08:00 ET | Aadi Bioscience
Company enters into collaborations with leading next generation sequencing (NGS) companies to facilitate trial enrollment for PRECISION 1, the Company’s Phase 2 registrational trialCollaborations will...
Aadi Logo.jpg
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
May 04, 2022 08:00 ET | Aadi Bioscience
LOS ANGELES, May 04, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined...
Aadi Logo.jpg
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
April 28, 2022 17:07 ET | Aadi Bioscience
LOS ANGELES, April 28, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for...
Aadi Logo.jpg
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
April 18, 2022 08:00 ET | Aadi Bioscience
LOS ANGELES, April 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for...
Aadi Logo.jpg
Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR)
April 08, 2022 13:09 ET | Aadi Bioscience
- First rigorous analysis estimates TSC1 and TSC2 definite impact alteration incidence in U.S. as approximately 12,000 advanced cancer patients in 2030 - Findings also identify highest frequency...
Aadi Logo.jpg
Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes
March 31, 2022 14:45 ET | Aadi Bioscience
LOS ANGELES, March 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in...